Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Today's Pre-Open Stock Movers
Medigus Ltd. (NASDAQ: MDGS) 41.6% HIGHER; announced a distribution agreement in Italy with INNOVAMEDICA S.p.A, a privately owned distributor of minimally invasive medical devices. Under terms of the four-year agreement which will take effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least 1M of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement.
Euroseas Ltd. (Nasdaq: ESEA) 31% HIGHER; announced that it signed a memorandum of agreement to purchase the M/V Capetan Tassos, a Panamax size drybulk carrier of 75,100 dwt built in 2000 in Japan for approximately $4.4 million. The vessel is expected to be delivered to the Company in January 2017
Juno Therapeutics, Inc. (Nasdaq: JUNO) 30% LOWER; announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the “ROCKET” trial. The clinical hold was initiated after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to recover.
Eli Lilly & Co. (NYSE: LLY) 14% LOWER; announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
Ferrellgas Partners (NYSE: FGP) 11.3% LOWER; declared a quarterly dividend of $0.10 per share, or $0.4 annualized. This is an 80.5% decrease from the prior dividend of $0.5125.
Nimble Storage (NYSE: NMBL) 10.2% LOWER; reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $102 million versus the consensus estimate of $101.99 million. GUIDANCE: Nimble Storage sees Q4 2017 EPS of ($0.13)-($0.15) versus the consensus of ($0.12). Revenue is seen at $112 million to $115 million vs $113.13 million.
Urban Outfitters (NASDAQ: URBN) 9.2% LOWER; reported Q3 EPS of $0.40, $0.04 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $862.5 million versus the consensus estimate of $869.07 million. Comps increased 1%.
Axovant Sciences (NYSE: AXON) 8.5% LOWER; down on Eli Lilly's Sola failure
Biogen (NASDAQ: BIIB) 8.4% LOWER; down on Eli Lilly's Sola failure
Veeva Systems (NYSE: VEEV) 6.4% HIGHER; reported Q3 EPS of $0.22, $0.06 better than the analyst estimate of $0.16. Revenue for the quarter came in at $142.8 million versus the consensus estimate of $135.67 million. GUIDANCE: Veeva Systems sees Q4 2017 EPS of $0.17, versus the consensus of $0.15. Veeva Systems sees Q4 2017 revenue of $145-146 million, versus the consensus of $140.4 million. Veeva Systems sees FY2017 EPS of $0.68, versus the consensus of $0.63. Veeva Systems sees FY2017 revenue of $538.9-539.9 million, versus the consensus of $526.8 million.
Kite Pharma (NASDAQ: KITE) 4.3% LOWER; lower on JUNO clinical hold
bluebird (NASDAQ: BLUE) 3.2% LOWER; lower on JUNO clinical hold
Merck & Co. (NYSE: MRK) 2.8% LOWER; down on Eli Lilly's Sola failure
HP, Inc. (NYSE: HPQ) 2.6% LOWER; reported Q4 EPS of $0.36, in-line with the analyst estimate of $0.36. Revenue for the quarter came in at $12.5 billion versus the consensus estimate of $11.88 billion. Guides Q1 EPS Midpoint Below Consensus
Abercrombie & Fitch (NYSE: ANF) 1.7% LOWER; Deutsche Bank downgraded from Hold to Sell with a price target of $13.00 (from $14.00)
GameStop (NYSE: GME) 1.6% LOWER; reported Q3 EPS of $0.49, $0.02 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.96 billion versus the consensus estimate of $1.99 billion. Comps fell 6.5%. GUIDANCE: GameStop sees Q4 2016 EPS of $2.23-$2.38, versus the consensus of $2.37. GameStop expects comparable store sales to range from -12.0% to -7.0%.
Valeant Pharmaceuticals (NYSE: VRX) 1.5% LOWER; Mizuho Securities downgraded from Neutral to Underperform with a price target of $11.00 (from $25.00).
Hewlett Packard Enterprise (NYSE: HPE) 1.4% LOWER; reported Q4 EPS of $0.61, in-line with the analyst estimate of $0.61. Revenue for the quarter came in at $12.5 billion versus the consensus estimate of $12.85 billion.
Twitter, Inc. (NYSE: TWTR) 1% LOWER; OTR Global downgraded from Mixed to Negative.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 12/02: (NVCN) (FIVE) (ULTA) Higher; (CVM) (WDAY) (AMBA) Lower (more...)
- Notable Mergers and Acquisitions 12/2: (VASC)/(TFX) (TWTR) (III) (BSX)/(NVCN)
- Notable Mergers and Acquisitions 11/30: (ZAYO) (LDL) (FLIR)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesDeutsche Bank, Twitter, Pre-Open Losers, Pre-Open Winners, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!